Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.

Khanna A, Thoms JAI, Stringer BW, Chung SA, Ensbey KS, Jue TR, Jahan Z, Subramanian S, Anande G, Shen H, Unnikrishnan A, McDonald KL, Day BW, Pimanda JE.

Mol Cancer Res. 2020 Feb 20. doi: 10.1158/1541-7786.MCR-19-0934. [Epub ahead of print]

PMID:
32079743
2.

Publisher Correction: A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2020 Jan 21;10(1):1185. doi: 10.1038/s41598-020-57850-w.

3.

Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.

Gartlan KH, Koyama M, Lineburg KE, Chang K, Ensbey KS, Kuns RD, Henden AS, Samson LD, Clouston AD, Lopez AF, MacDonald KPA, Hill GR.

Blood Adv. 2019 Oct 8;3(19):2859-2865. doi: 10.1182/bloodadvances.2019000053.

4.

IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling.

Wilkinson AN, Chang K, Kuns RD, Henden AS, Minnie SA, Ensbey KS, Clouston AD, Zhang P, Koyama M, Hidalgo J, Rose-John S, Varelias A, Vuckovic S, Gartlan KH, Hill GR.

Blood. 2019 Dec 5;134(23):2092-2106. doi: 10.1182/blood.2019000396.

PMID:
31578204
5.

Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.

Lim YC, Ensbey KS, Offenhäuser C, D'souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Kim B, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW.

Neuro Oncol. 2020 Feb 20;22(2):216-228. doi: 10.1093/neuonc/noz159.

PMID:
31504812
6.

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW.

Acta Neuropathol. 2019 Dec;138(6):1033-1052. doi: 10.1007/s00401-019-02069-x. Epub 2019 Aug 28.

7.

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z. Erratum in: Sci Rep. 2020 Jan 21;10(1):1185.

8.

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW.

Cancers (Basel). 2018 Dec 17;10(12). pii: E519. doi: 10.3390/cancers10120519.

9.

Granule neuron precursor cell proliferation is regulated by NFIX and intersectin 1 during postnatal cerebellar development.

Fraser J, Essebier A, Brown AS, Davila RA, Sengar AS, Tu Y, Ensbey KS, Day BW, Scott MP, Gronostajski RM, Wainwright BJ, Boden M, Harvey TJ, Piper M.

Brain Struct Funct. 2019 Mar;224(2):811-827. doi: 10.1007/s00429-018-1801-3. Epub 2018 Dec 3.

PMID:
30511336
10.

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.

Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG.

Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33.

11.

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ.

Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.

12.

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.

Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S.

Mol Imaging. 2015;14:385-99.

PMID:
26218510
13.

Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbey KS, Walker DG, Boyd AW, Lavin MF.

Mol Oncol. 2014 Dec;8(8):1603-15. doi: 10.1016/j.molonc.2014.06.012. Epub 2014 Jun 27.

14.

Glioma surgical aspirate: a viable source of tumor tissue for experimental research.

Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW.

Cancers (Basel). 2013 Apr 3;5(2):357-71. doi: 10.3390/cancers5020357.

15.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

16.

A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells.

Lim YC, Roberts TL, Day BW, Harding A, Kozlov S, Kijas AW, Ensbey KS, Walker DG, Lavin MF.

Mol Cancer Ther. 2012 Sep;11(9):1863-72. doi: 10.1158/1535-7163.MCT-11-1044. Epub 2012 Jul 6.

17.

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW.

Neuro Oncol. 2011 Nov;13(11):1202-12. doi: 10.1093/neuonc/nor119. Epub 2011 Aug 16.

Supplemental Content

Loading ...
Support Center